Poolbeg Pharma
POLB · AIM · Health Care · mcap £52m · 6.9p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 06 Oct 26 | POLB001 CRS Patent Granted in South Korea
Cancer Immunotherapy-Induced CRS Patent Granted in South Korea |
+2.9% | |
| 29 Sep 26 | Results | Half-year Results
Interim Results for the six months to 30 June 2026 |
+0.7% |
| 28 Sep 26 | POLB 001 TOPICAL trial recruitment update
28 September 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, reaffirms that participant recruitm |
+3.5% | |
| 24 Sep 26 | Interim data from POLB 001 TOPICAL clinical trial
Interim data from POLB 001 TOPICAL clinical trial |
−12.7% | |
| 14 Sep 26 | Holding | Holding(s) in Company | |
| 03 Sep 26 | Key Conference Participation in September 2026
Poolbeg Pharma to Participate in Key Conferences in September 2026 |
+4.1% | |
| 23 Jul 26 | Holding | Holding(s) in Company | |
| 22 Jul 26 | Holding | Holding(s) in Company | |
| 21 Jul 26 | Notice of Allowance for POLB 001 patent in Israel
Notice of Allowance received for POLB 001 Cancer Immunotherapy-induced CRS patent in Israel |
+0.6% | |
| 14 Jul 26 | Fundraise | Placing to raise £3.5 million
CERTAIN OF THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU 596/2014) AS THE SAME CURRENTLY FORMS PART OF EN |
−13.6% |
| 13 Jul 26 | First patient dosed in POLB 001 TOPICAL trial
First Patient Dosed in the POLB 001 TOPICAL Clinical Trial |
+0.0% | |
| 30 Jun 26 | POLB 001 patent granted in South Africa
POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza |
+1.5% | |
| 16 Jun 26 | European patent granted for POLB 001 in CRS
Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS |
+3.7% | |
| 16 Jun 26 | Director dealing | Director/PDMR Shareholding | |
| 11 Jun 26 | Preclinical data posters presented at EHA Congress
Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress |
+0.7% | |
| 11 Jun 26 | POLB 001 TOPICAL Site Activation
Poolbeg Pharma Announces Successful Site Activation for POLB 001 TOPICAL Clinical Trial |
+0.7% | |
| 09 Jun 26 | Results of AGM & Change of Registered Address
Results of AGM & Change of Registered Address |
−2.5% | |
| 26 May 26 | Pre-IND Meeting with the FDA for POLB 001
Pre-IND Meeting with the FDA for POLB 001 |
+10.1% | |
| 13 May 26 | POLB 001 poster to be presented at EHA 2026
POLB 001 poster to be presented at EHA 2026 Congress |
+5.6% | |
| 11 May 26 | POLB 001 CRS patent granted in Canada
POLB 001 cancer immunotherapy-induced CRS patent granted in Canada |
+3.4% | |
| 07 May 26 | Results | Annual Report & AGM Notice
7 May 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, confirms that the Company's Annual Report |
+1.1% |
| 28 Apr 26 | Results | Results for the year ended 31 December 2025
Results for the year ended 31 December 2025 |
−3.4% |
| 15 Apr 26 | MHRA grants CTA for the POLB 001 TOPICAL trial
MHRA grants Clinical Trial Authorisation for the TOPICAL trial and independent research confirms significant commercial opportunity for POLB 001 |
+2.2% | |
| 31 Mar 26 | Significant milestone for Poolbeg's IP portfolio
Grant of first POLB 001 cancer immunotherapy-induced CRS patent |
+3.6% | |
| 12 Mar 26 | Appointment of Dr Adrian Kilcoyne to SAB
Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board |
+0.0% | |
| 09 Feb 26 | Holding | Holding(s) in Company | |
| 28 Jan 26 | POLB 001 LPS Challenge Trial Paper Published
Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology |
+8.6% | |
| 27 Jan 26 | Routine | Exercise of Options & Total Voting Rights | |
| 18 Dec 25 | Letter to Shareholders – 2025 a year of progress
Letter to Shareholders - 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected |
+1.3% | |
| 08 Dec 25 | POLB 001 to feature in CRS research programme
POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme |
+5.5% | |
| 20 Nov 25 | POLB 001 European Patent granted
20 November 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent O |
+3.3% |
Company filings. Not investment advice.